Company Profile

Spectrum Pharmaceuticals Inc (AKA: Talon Therapeutics, Inc.~NeoTherapeutics, Inc~Advanced Immunotherapeutics)
Profile last edited on: 5/13/22      CAGE: 5BDW2      UEI: SC4WFM7J1EJ3

Business Identifier: Novel therapeutic drugs to treat neurodegenerative diseases and conditions
Year Founded
1987
First Award
1991
Latest Award
1994
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

11500 South Eastern Avenue Suite 240
Henderson, NV 89052
   (702) 835-6300
   N/A
   www.sppirx.com
Location: Multiple
Congr. District: 03
County: Clark

Public Profile

Originally doing business as NeoTherapeutics and then as Advanced Immonotherapeutics, in 2002 the firm changed its name Spectrum Pharmaceuticals. With limited SBIR involvement and that soon after firm was establsihed, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) had six drug products, including FUSILEV for patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has an aggressive program of licensing in and out nationally and internationally having agreements with a rnage of fir to include Cell Therapeutics, Inc.; Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; Allergan, Inc.; Nippon Kayaku Co., LTD.; Onxeo DK; Hanmi Pharmaceutical Company.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : SPPI
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1994 2 NIH $384,617
Project Title: AIT 082 a drug for treatment of Alzheimer's disease

Key People / Management

  Rajesh C Shrotriya -- Chairman, Chief Exec. Officer, Chairman of Product Acquisition Committee and Cha

  Alvin J Glasky -- President

  David Mareske

Company News

There are no news available.